- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- At least 23,000 die from antibiotic-resistant infections each year, CDC finds
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
RALEIGH, N.C. — The U.S. Patent and Trademark Office has awarded Salix Pharmaceuticals three patents related to a drug used for travelers’ diarrhea.
Salix announced Wednesday that it had secured patents for the drug Xifaxan (rifaximin) covering its methods of treating travelers’ diarrhea, as well as two related to the drug’s chemical composition.
The patents are set to expire between 2024 and 2029.